Anavex Life Sciences Corp (AVXL)

[PeterKarol]

Thank you for you thoughtful post. Regarding point 6: it is hard to compare one drug study to another, see last post in piotrpeterblog.com, where I broached on the subject of dropouts since the results can be “excellent” just for few patients. Culling patients yet cannot stand the trial of time. After 6 years there is barely anybody standing. After 3 years about ~63% are dropouts for general mix of patients. The power of studies touch on the question of statistical validity of data results, not the number dropouts who deteriorated so much that either get institutionalized or go into final stage. I am total ignoramus when it comes to statistical models but I try to navigate using basic math and logic. Nevertheless I thank for citing those references and I think our collective efforts next to be getting at the meaning of data for the general population. It might be that soon BIIB037 becomes the drug at least in MSM but there is silver lining to it to because people might start believing again that there somewhere is the cure.